Evidence map›Paper›PMID 34885116›Full record

ArticleCancers2021

Integrin αvβ6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions.

Bertine W Huisman, Merve Cankat, Tjalling Bosse, Alexander L Vahrmeijer, Robert Rissmann, Jacobus Burggraaf, Cornelis F M Sier, Mariette I E van Poelgeest

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bertine W HuismanCenter for Human Drug Research, 2333 CL Leiden, The Netherlands.ORCID 0000-0002-0807-0658
Merve CankatCenter for Human Drug Research, 2333 CL Leiden, The Netherlands.
Tjalling BosseDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Alexander L VahrmeijerDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Robert RissmannCenter for Human Drug Research, 2333 CL Leiden, The Netherlands.
Jacobus BurggraafCenter for Human Drug Research, 2333 CL Leiden, The Netherlands.
Cornelis F M SierDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-4337-2758
Mariette I E van PoelgeestCenter for Human Drug Research, 2333 CL Leiden, The Netherlands.
Leiden University Medical Center · NLLeiden University · NL

Funding

Bontiusstichting - LUMC n.a.Marie Curie H2020-MSCA-RISE-2018, ID 777682-CANCERMarie Curie H2020-MSCA-RISE 2019, ID 872860-PRISAR2Marie Curie H2020-WIDESPREAD-2018-Twinning 852985-SIMICA
6 · The paper itself

Abstract

Surgical removal of vulvar squamous cell carcinoma (VSCC) is associated with significant morbidity and high recurrence rates. This is at least partially related to the limited visual ability to distinguish (pre)malignant from normal vulvar tissue. Illumination of neoplastic tissue based on fluorescent tracers, known as fluorescence-guided surgery (FGS), could help resect involved tissue and decrease ancillary mutilation. To evaluate potential targets for FGS in VSCC, immunohistochemistry was performed on paraffin-embedded premalignant (high grade squamous intraepithelial lesion and differentiated vulvar intraepithelial neoplasia) and VSCC (human papillomavirus (HPV)-dependent and -independent) tissue sections with healthy vulvar skin as controls. Sections were stained for integrin αvβ6, CAIX, CD44v6, EGFR, EpCAM, FRα, MRP1, MUC1 and uPAR. The expression of each marker was quantified using digital image analysis. H-scores were calculated and percentages positive cells, expression pattern, and biomarker localization were assessed. In addition, tumor-to-background ratios were established, which were highest for (pre)malignant vulvar tissues stained for integrin αvβ6. In conclusion, integrin αvβ6 allowed for the most robust discrimination of VSCCs and adjacent premalignant lesions compared to surrounding healthy tissue in immunohistochemically stained tissue sections. The use of an αvβ6 targeted near-infrared fluorescent probe for FGS of vulvar (pre)malignancies should be evaluated in future studies.

Indexed as

dVINfluorescence-guided surgeryHSILintegrin αvβ6squamous carcinomavulva

Identifiers

PMID34885116
PMCPMC8656970
OpenAlexW3214933987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.